<DOC>
	<DOCNO>NCT00523237</DOCNO>
	<brief_summary>The purpose study : - Provide raltegravir subject HIV undetectable viral load experience injection site reaction ( ISR ) Enfuvirtide , - Monitor safety efficacy raltegravir , - Assess change quality life patient switch Enfuvirtide raltegravir</brief_summary>
	<brief_title>RAL-eve Study : Raltegravir Substitution Study</brief_title>
	<detailed_description>We enrol virologically suppress HIV-1 infected patient injection site reaction switch enfuvirtide raltegravir . At baseline , enfuvirtide switch raltegravir without additional change antiretroviral regimen allow . Viral load , T-cells , toxicity evaluate baseline , 2 , 4 , 12 24 week . Adherence injection site reaction evaluate baseline , 4 , 12 24 week . The single-copy assay use measure HIV RNA level screen , baseline 12 24 week .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>1 . HIV1 infection , document licensed ELISA test kit confirm Western blot time prior study entry . 2 . ART least 6 month prior study entry regimen include enfuvirtide . 3 . Selfdefined infusion site reaction enfuvirtide ( usually painful inflammatory nodule ) 4 . No change ART regimen least 3 month prior study entry . 5 . CD4+ cell count &gt; 50/mm3 screening ( obtain within 60 day prior study entry ) . 6 . Documentation HIV1 RNA limit quantification ultrasensitive assay 7 . All HIV1 RNA level obtain within 6 month prior study entry limit quantification test , except explain section 4.1.6 single detectable viral load &lt; 50 copy &lt; 200 copy last 6 month . 8 . Laboratory value obtain within 60 day prior entry : Absolute neutrophil count ( ANC ) &gt; 750/mm3 Hemoglobin &gt; 9.0 g/dL female subject &gt; 10.0 g/dL male subject Platelet count &gt; 50,000/mm3 Calculated creatinine clearance ( CrCl ) &gt; 30 mL/min , estimate CockcroftGault equation* AST ( SGOT ) , ALT ( SGPT ) , alkaline phosphatase &lt; 5 x ULN Total bilirubin &lt; 2.5 x ULN . If subject take indinavir atazanavircontaining regimen time screening , total bilirubin &lt; 5 x ULN acceptable . 9 . For female reproductive potential need negative serum urine pregnancy test within 48 hour prior entry . 10 . Men woman age &gt; 18 year . 11 . Ability willingness subject provide inform consent . 1 . Unstable clinical condition , unstable cardiac disease , cancer require ongoing chemotherapy radiation therapy , medical condition , opinion investigator , would preclude subject safely undergo study procedure . 2 . Breastfeeding pregnancy . 3 . An opportunistic infection within 60 day prior entry . 4 . Known allergy/sensitivity hypersensitivity component study drug ( ) formulation . 5 . Active drug alcohol use dependence , opinion Protocol Director , would interfere adherence study requirement . 6 . Receipt nonHIV vaccination within 30 day prior study entry plan receipt vaccination study . 7 . Plan change background ART within 24 week study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>